Your browser is no longer supported. Please, upgrade your browser.
Settings
MACK Merrimack Pharmaceuticals, Inc. daily Stock Chart
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.37 Insider Own0.10% Shs Outstand13.39M Perf Week2.90%
Market Cap90.25M Forward P/E- EPS next Y- Insider Trans- Shs Float12.80M Perf Month16.01%
Income-45.00M PEG- EPS next Q- Inst Own57.10% Short Float4.27% Perf Quarter8.19%
Sales- P/S- EPS this Y-9.50% Inst Trans15.12% Short Ratio9.20 Perf Half Y8.89%
Book/sh3.00 P/B2.25 EPS next Y- ROA-31.90% Target Price4.00 Perf Year24.35%
Cash/sh2.98 P/C2.26 EPS next 5Y5.60% ROE-46.20% 52W Range3.34 - 7.50 Perf YTD74.61%
Dividend- P/FCF- EPS past 5Y19.20% ROI- 52W High-10.13% Beta1.96
Dividend %- Quick Ratio8.60 Sales past 5Y- Gross Margin- 52W Low101.79% ATR0.30
Employees27 Current Ratio8.60 Sales Q/Q- Oper. Margin- RSI (14)62.04 Volatility4.57% 4.92%
OptionableYes Debt/Eq0.00 EPS Q/Q46.90% Profit Margin- Rel Volume1.44 Prev Close6.74
ShortableYes LT Debt/Eq0.00 EarningsAug 09 BMO Payout- Avg Volume59.38K Price6.74
Recom3.50 SMA203.53% SMA5012.30% SMA20019.33% Volume85,392 Change0.00%
Oct-07-16Downgrade JP Morgan Overweight → Neutral
May-27-16Initiated Robert W. Baird Neutral $8
Dec-23-15Reiterated Mizuho Buy $16 → $13
Oct-27-15Reiterated Oppenheimer Outperform $13 → $15
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
Aug-22-19 08:30AM  JFL Capital Issues Letter to Fellow Merrimack Stockholders PR Newswire
Aug-16-19 09:15AM  Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019 Business Wire
Jul-25-19 08:30AM  Merrimack Declares $20 Million Special Dividend PR Newswire +7.59%
May-31-19 07:34AM  The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering Benzinga -6.09%
06:21AM  Merrimack axes remaining staff, execs after selling assets to New York startup American City Business Journals
May-30-19 04:05PM  Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend PR Newswire
May-10-19 07:30AM  Merrimack Reports First Quarter 2019 Financial Results PR Newswire
May-06-19 01:46PM  COMM 2014-UBS2 Mortgage Trust -- Moody's affirms ten classes of COMM 2014-UBS2 Moody's
May-03-19 05:43PM  COMM 2014-UBS2 Mortgage Trust -- Moody's affirms ten classes of COMM 2014-UBS2 Moody's
Apr-18-19 03:07PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK GlobeNewswire
Apr-16-19 04:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK ACCESSWIRE
Apr-12-19 01:57PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK GlobeNewswire
Apr-09-19 05:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK PR Newswire
Apr-08-19 10:12AM  Merrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation ACCESSWIRE
Apr-05-19 08:29AM  The Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather Upset Simply Wall St. -16.41%
07:48AM  The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership Benzinga
Apr-04-19 05:58PM  Merrimack shelves another cancer drug, plans more layoffs American City Business Journals
04:15PM  Merrimack Discontinues Development of MM-310 PR Newswire
Mar-07-19 09:06AM  Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 Zacks
Mar-06-19 07:00AM  Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire +8.63%
Feb-12-19 07:35AM  New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-11-19 09:39AM  Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely? Zacks
Jan-28-19 10:19PM  Edited Transcript of MACK earnings conference call or presentation 7-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Dec-10-18 05:00PM  John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman GlobeNewswire
Nov-09-18 10:31AM  Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3 Zacks
08:45AM  Research Report Identifies Merrimack Pharmaceuticals, PNM Resources, Inc. (Holding Co.), Carrols Restaurant Group, American Axle & Manufacturing, CBIZ, and Nova Measuring Instruments with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-08-18 10:17AM  Merrimack to shelve lead cancer drug, lay off most of workforce American City Business Journals
Nov-07-18 06:45AM  Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review PR Newswire +9.20%
Nov-06-18 01:44PM  Merrimack Pharmaceuticals Q3 Earnings Preview Benzinga
Nov-05-18 07:55AM  5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings Zacks
Oct-31-18 04:05PM  Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call PR Newswire
Oct-24-18 11:19AM  Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod Zacks -6.67%
Oct-19-18 10:48AM  Merrimack's String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials Benzinga -22.29%
07:46AM  Merrimack Pharmaceuticals' stock plummets toward record low after cancer drug trial terminated MarketWatch
06:00AM  Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility PR Newswire
Oct-16-18 07:30AM  Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-11-18 05:16PM  Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts Zacks
Sep-20-18 07:00AM  Merrimack Receives $5 Million Milestone Payment from Shire PR Newswire
Sep-06-18 10:35AM  Merrimack (MACK) Up 6.7% Since Last Earnings Report: Can It Continue? Zacks -5.75%
06:50AM  Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC) PR Newswire
Sep-05-18 12:06PM  Edited Transcript of MACK earnings conference call or presentation 7-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Sep-04-18 10:07AM  Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank Zacks
Aug-16-18 08:00AM  Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX New Research Emphasizes Economic Growth GlobeNewswire
Aug-08-18 10:20AM  Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2 Zacks
Aug-07-18 08:18AM  Merrimack (MACK) Reports Wider-than-Expected Q2 Loss Zacks
06:30AM  Merrimack Reports Second Quarter 2018 Financial Results PR Newswire
06:30AM  Merrimack Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 12:09PM  Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings? Zacks
Jul-31-18 04:10PM  Merrimack Announces Timing of Second Quarter 2018 Investor Conference Call PR Newswire
Jul-10-18 04:55PM  Ex-biopharmaceutical employees convicted in U.S. of insider trading Reuters
Jul-02-18 04:15PM  Merrimack Secures $25 Million Debt Facility with Hercules Capital PR Newswire
Jun-27-18 08:12AM  Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod Zacks +7.26%
Jun-26-18 07:51PM  Ex-Akebia employee jailed for night as insider trading trial starts Reuters
08:12AM  Merrimack Crashes as Phase II Pancreatic Cancer Study Fails Zacks
Jun-25-18 07:55AM  Merrimack to scrap development of pancreatic cancer treatment Reuters -43.83%
07:54AM  UPDATE: Merrimack Pharma shares slide 34% after trial of pancreatic cancer treatment fails to meet main goals MarketWatch
07:29AM  Merrimack to scrap development of pancreatic cancer treatment Reuters
07:20AM  Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer PR Newswire
Jun-15-18 08:41AM  Options Traders Expect Huge Moves in Merrimack Pharmaceuticals (MACK) Stock Zacks
Jun-07-18 09:15AM  Why is Merrimack (MACK) Up 6.3% Since Its Last Earnings Report? Zacks
Jun-04-18 01:57PM  Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-29-18 08:15AM  Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience, Merrimack Pharmaceuticals, and Energizer with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM  Merrimack to Present at the 2018 American Society of Clinical Oncology Annual Meeting PR Newswire
May-09-18 10:49AM  Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1 Zacks
May-08-18 06:25AM  Merrimack Reports First Quarter 2018 Financial Results PR Newswire
May-03-18 10:13AM  What's in the Cards for Merrimack (MACK) in Q1 Earnings? Zacks
May-01-18 07:00AM  Merrimack Announces Timing of First Quarter 2018 Investor Conference Call PR Newswire
Apr-09-18 07:30AM  Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting PR Newswire
Apr-04-18 08:15AM  Consolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail Fundamental Analysis, Key Performance Indications GlobeNewswire +5.74%
Mar-14-18 07:30AM  Wired News Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung Cancer ACCESSWIRE
Mar-13-18 09:45AM  Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 Zacks
Mar-12-18 07:06PM  Edited Transcript of MACK earnings conference call or presentation 12-Mar-18 12:30pm GMT Thomson Reuters StreetEvents -10.28%
07:30AM  Merrimack Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:27AM  Merrimack Provides Business Update and Reports 2017 Financial Results PR Newswire
06:25AM  Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer PR Newswire
Mar-05-18 07:00AM  Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference PR Newswire
Feb-27-18 05:11AM  Are Earnings Prospects Improving For Loss-Making Merrimack Pharmaceuticals Incs (NASDAQ:MACK)? Simply Wall St.
Feb-26-18 06:55AM  Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer PR Newswire
Feb-23-18 09:10AM  What's in the Cards for Merrimack (MACK) in Q4 Earnings? Zacks
Feb-20-18 07:00AM  Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology PR Newswire
Feb-15-18 07:00AM  Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference PR Newswire
Feb-06-18 08:25AM  New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-04-18 08:00AM  Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-11-17 04:12AM  Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound? Zacks
Nov-30-17 06:50AM  Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors PR Newswire
Nov-20-17 08:04PM  With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Incs (MACK) Management Done A Good Job? Simply Wall St.
Nov-14-17 07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
Nov-13-17 08:31PM  Edited Transcript of MACK earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 09:45AM  Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up Zacks
Nov-08-17 10:15AM  Merrimack beats 3Q profit forecasts Associated Press
08:25AM  Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss Zacks
06:40AM  Merrimack Reports Third Quarter 2017 Financial Results PR Newswire
06:30AM  Merrimack Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-06-17 10:17AM  What's in the Cards for Merrimack (MACK) in Q3 Earnings? Zacks
Nov-01-17 07:10AM  Featured Company News - FDA Granted Orphan Drug Designation to Merrimack's MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung Cancer ACCESSWIRE
06:55AM  Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call PR Newswire
Oct-30-17 09:45AM  Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121 SmarterAnalyst
09:32AM  NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers TheStreet.com
06:55AM  Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer PR Newswire
Oct-28-17 10:41AM  Have Investors Already Priced In Merrimack Pharmaceuticals Incs (MACK) Growth? Simply Wall St.
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aryeh JasonSee Explanation of ResponsesJul 16Buy5.443021,6433,802Jul 18 07:38 PM
Aryeh JasonSee Explanation of ResponsesJul 12Buy5.683,40019,3243,500Jul 15 04:32 PM
Aryeh JasonSee Explanation of ResponsesJul 11Buy5.71100571100Jul 15 04:32 PM
JFL Capital Management, LLCSee Explanation of ResponsesJul 02Buy5.8517,131100,182739,676Jul 02 07:01 PM
JFL Capital Management, LLCSee Explanation of ResponsesJul 01Buy6.009,59357,586729,569Jul 02 07:01 PM
JFL Capital Management, LLCSee Explanation of ResponsesJun 28Buy5.9523,564140,088723,910Jul 02 07:01 PM
22NW, LPSee Explanation of ResponsesApr 17Buy6.0016,20097,1561,241,896Apr 17 08:15 PM
22NW, LPSee Explanation of ResponsesApr 16Buy5.9520,450121,6371,225,696Apr 17 08:15 PM
22NW, LPSee Explanation of ResponsesApr 15Buy5.7330,110172,5301,205,246Apr 17 08:15 PM
JFL Capital Management, LLCSee Explanation of ResponsesApr 08Buy5.7310,99062,933710,008Apr 09 06:30 PM
22NW, LPSee Explanation of ResponsesApr 08Buy5.8132,873191,0351,175,136Apr 09 06:39 PM
22NW, LPSee Explanation of ResponsesApr 05Buy6.1250,000305,7601,142,263Apr 09 06:39 PM
JFL Capital Management, LLCSee Explanation of ResponsesApr 05Buy5.9526,288156,466703,524Apr 09 06:30 PM